Benitec Says USPTO Reverses Rejection of US Patent

The patent fell under USPTO scrutiny as part of patent-infringement litigation the company initiated against now-defunct expressed RNAi shop Nucleonics, and certain claims within the intellectual property were rejected by the patent office

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.